Pharmaceutical nanotechnology : innovation and production / edited by Jean Cornier [and three others].

Format:

Book

Contributor:

Cornier, Jean, editor.

Language:

English

Subjects (All):

Drug development.

Drugs--Design.

Drugs.

Physical Description:

1 online resource (807 pages) : illustrations (some color)

Edition:

1st ed.

Place of Publication:

Weinheim, Germany : Wiley-VCH, 2017.

Summary:

With its focus on concrete methods and recent advances in applying nanotechnology to develop new drug therapies and medical diagnostics, this book provides an overall picture of the field, from the fundamentals of nanopharmacy with the characterisation and manufacturing methods to the role of nanoparticles and substances. Actual examples of utilization include drug development issues, translation to the clinic, market prospects, and industrial commercialization aspects. The applications described are taken from cancer treatment as well as other major therapeutic areas, such as infectious diseases and dermatology. An in-depth discussion on safety, regulatory, and societal aspects rounds off the book. Written by a top team of editors and authors composed of the leading experts in Europe and the USA who have pioneered the field of nanopharmacy!

Contents:

Pharmaceutical Nanotechnology: Innovation and Production

Series Editor Preface

About the Series Editor

Contents

Foreword

Industrial Requirement on Nanopharmacy Research

Introduction

Part One: Entry to the Nanopharmacy Revolution

1: History: Potential, Challenges, and Future Development in Nanopharmaceutical Research and Industry

1.1 Nanopharmaceuticals in Cancer Therapy

1.2 Nanoparticles Actively Using the Host Machinery

1.3 Nanopharmaceuticals for Oral Administration and Long-Acting Injectable Therapy

1.4 Bridging Future Nanomedicines to Commercialization

1.5 Future Outlook

Acknowledgments

References

2: Nanoscale Drugs: A Key to Revolutionary Progress in Pharmacy and Healthcare

2.1 Introduction

2.1.1 Setting the Stage

2.1.2 Definition and Size Aspects

2.1.3 Nanopharmacy: Interdisciplinary Medicine

2.2 Nanopharmacy Concepts to Improve the Safety and Efficacy of Medicines

2.2.1 Overcoming the Solubility Barrier

2.2.2 Controlling Drug Release

2.2.2.1 Sustained Release

2.2.2.2 Stimuli-Responsive Release

2.2.3 Overcoming Biological Barriers

2.2.3.1 Epithelial-Endothelial Barriers

2.2.3.2 Noncellular Barriers

2.2.4 Targeting

2.2.4.1 Active Targeting

2.2.4.2 Passive Targeting

2.3 Technical Realization of Nanopharmaceuticals

2.3.1 Nanosized APIs

2.3.2 Organic Nanocarriers

2.3.2.1 Lipid-Based Nanocarriers

2.3.2.2 Polymer-Based Nanocarriers

2.3.2.3 Protein-Based Nanoparticles

2.3.3 Inorganic Nanoparticles

2.4 Safety of Nanopharmaceuticals

2.5 Present and Future of Nanopharmacy

3: The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs

3.1 Introduction

3.2 First Generation of Nanopharmaceuticals: From Drug Molecules to Nanodrugs.

3.2.1 Making New Therapies Happen: The Example of Nucleic Acid Therapeutics

3.2.1.1 Making Nanodrugs Smarter: Multifunctional Nanodrugs

3.3 Conclusion

4: Understanding and Characterizing Functional Properties of Nanoparticles

4.1 Introduction

4.1.1 Key Concepts: Size Matters, Biological Interactions

4.1.2 Link Between Material Properties and Characterization for Differing Timescales of Biological Interaction

4.1.2.1 Early Times

4.1.2.2 Degradation of Surface

4.1.2.3 Long Timescales

4.1.2.4 Priorities

4.2 The Approach to Characterization

4.2.1 The Nature of Early-Stage Biological Recognition

4.2.1.1 Epitope and Recognition Motif Mapping

4.2.1.2 Forces, Dynamics, and Other Processes at Bio-Nano interface

4.2.2 The Nature of the Intracellular Bio-Nano Interface

4.2.3 The Future of the Bio-Nano Interface, Bionanoscience, and Nanomedicine

5: Omics-Based Nanopharmacy: Powerful Tools Toward Precision Medicine

5.1 Introduction

5.2 Precision Medicine

5.2.1 Precision Oncology

5.2.2 Therapeutic mAbs

5.2.3 Therapeutic Small-Molecules Inhibitors

5.2.4 Chimeric Antigen Receptors (CARs)

5.3 "OMICS" - New Era in Understanding Pathology

5.3.1 Next-Generation Sequencing (NGS)

5.3.2 The Identification of "Clear-Cut" Biomarkers Using State-of-the-Art Proteomics

5.3.3 Personal OMICS Profiling

5.3.4 Single-Cell Sequencing

5.4 Nanomedicine

5.4.1 Personalized Oncology Using Nanomedicine

5.4.1.1 Passive Tissue Targeting vs. Active Cellular Targeting

5.4.2 RNAi: A powerful Approach for Cancer Personalized Therapy

5.5 Future Outlook

Part Two: Fundamentals of Nanotechnology in Pharmacy

6: Nanostructures in Drug Delivery

6.1 Introduction

6.2 Nanocarrier Classification

6.2.1 Inorganic Nanostructures.

6.2.2 Organic Nanostructures

6.2.2.1 Drug Nanocrystals

6.2.2.2 Matrix Systems

6.2.2.3 Vesicular Systems

6.3 Drug Loading and Release

6.3.1 Hydrophobic Drugs

6.3.2 Hydrophilic Drugs

6.3.3 Macromolecular Drugs

6.4 General Discussion and Conclusions

7: Characterization Methods: Physical and Chemical Characterization Techniques

7.1 The Need for Nanomedicine-Specific Characterization

7.2 The Assay Cascade: From Basic Properties to Complex Interactions

7.3 Physicochemical Characterization of Pristine Nanoparticles

7.3.1 Size, Size Distribution, and Topology

7.3.1.1 Batch Particle Sizing Techniques

7.3.1.2 Single Particle Sizing Techniques

7.3.1.3 Separation- and Fractionation-Based Sizing Techniques

7.3.2 Surface Characteristics and Functionalization

7.3.2.1 Zeta (ζ) Potential

7.3.2.2 Chemical Surface Functionalization and Targeting

7.3.3 Composition and Purity

7.4 Characterization of Nanoparticles in the Biological Environment

7.4.1 Sterility and Endotoxin

7.4.2 Surface Adsorption: the Protein Corona

7.4.3 Drug Release

7.5 Conclusions and Future Outlook

8: Nanoparticle Characterization Methods: Applications of Synchrotron and Neutron Radiation

8.1 Advanced Characterization: Synchrotron Light and Neutron Sources

8.2 Application Examples

8.2.1 Synchrotron Micro-X-ray Fluorescence and Micro-X-ray Absorption Spectroscopy

8.2.2 Pair Distribution Function

8.2.3 Small-angle X-ray Scattering

8.2.4 Small-Angle Neutron Scattering and Neutron Reflectometry

8.3 Going Beyond Characterization Using Synchrotron X-rays: Nanoparticles for Diagnostic and Therapeutic Approaches

8.4 Looking Ahead and Conclusions

9: Overview of Techniques and Description of Established Processes

9.1 Introduction.

9.2 Processing of Liquid Drug Carrier Formulations

9.2.1 Colloidal Lipid Emulsions

9.2.1.1 General Aspects and Composition

9.2.1.2 Preparation Process of Intravenous Fat Emulsions

9.2.1.3 Preparation of the Adjuvant Emulsion MF59

9.2.2 Liposomes

9.2.2.1 General Aspects and Composition

9.2.2.2 Preparation of Liposomal Dispersions

9.2.2.3 Drug Incorporation into Liposomes and Other Colloidal Lipid Structures

9.2.2.4 DepotFoam® Technology

9.2.2.5 Sterilization of Liposomes

9.2.2.6 Drying of Liposomal Dispersions

9.2.3 Polymeric Nanoparticles

9.2.3.1 General Aspects

9.2.3.2 Abraxane®

9.3 Drug Nanoparticles and Process Chains to Solid Formulations

9.3.1 Drug Particle Size-Determining Processes

9.3.1.1 Comminution Processes (Top-Down Methods)

9.3.1.2 Bottom-Up Processes

9.3.1.3 Hybrid/Combinative Methods

9.3.2 Drying Methods and Further Processing

9.3.2.1 Freeze-Drying

9.3.2.2 Spray-Drying

9.3.2.3 Spray-Coating, Granulation, and Pelletization

9.3.2.4 Other Conversion Methods

9.3.3 Marketed Products Containing Drug Nanoparticles

9.3.3.1 Rapamune®

9.3.3.2 Emend®

9.4 Industrial Status and Framework

9.5 Perspectives for Academia, Industry, and Regulatory Authorities

10: Nanopharmacy: Exploratory Methods for Polymeric Materials

10.1 Introduction

10.2 Rationale for the Use of Polymers in Nanomedicines

10.3 Polymer Structures and Properties

10.3.1 Polymer Morphology

10.3.2 Polymer Structures for Drug Delivery - Micelles and Vesicles

10.4 Formulation of Copolymers into Micelles, Vesicles, and Nanoparticles

10.4.1 Investigational Formulations - Stimuli-Responsive Polymers

10.5 Conjugation of Polymers to Drugs and Proteins

10.5.1 Polymer-drug Conjugates

10.5.2 PEG-Protein Conjugates

10.5.3 Properties of PEGylated Proteins.

10.5.4 Preparation of PEGylated Proteins

10.5.5 Moving Beyond Protein PEGylation

10.6 Recent Advances in Polymer Synthesis for Therapeutic Applications

10.6.1 Biodegradable Polymers for Nanomedicines

10.6.2 Classification of Biodegradable Polymers

10.6.2.1 Naturally Occurring Biodegradable Polymers for Nanomedicine

10.6.2.2 Synthetic Biodegradable Polymers for Nanomedicine

10.6.3 Mechanisms of Polycondensation Reactions

10.6.3.1 Fischer Esterification

10.6.3.2 Transesterification

10.6.4 Ring-Opening Polymerization

10.6.4.1 Anionic ROP

10.6.4.2 Cationic ROP

10.6.4.3 Coordination-Insertion ROP

10.6.5 Examples of Synthetic Polyesters as Investigational Nanomedicines

10.6.5.1 Poly(caprolactone)

10.6.5.2 Poly(anhydrides)

10.6.5.3 Poly(trimethylene Carbonate)

10.6.5.4 Polyesters in Development

10.6.5.5 Poly(esters) of Lactide and Glycolide

10.7 Controlled Radical Polymerization (CRP)

10.7.1 Atom Transfer Radical Polymerization (ATRP)

10.7.2 Reversible Addition Fragmentation Chain Transfer (RAFT) Polymerization

10.8 Concluding Remarks

11: Overview and Presentation of Exploratory Methods for Manufacturing Nanoparticles/"Inorganic Materials

11.1 Introduction

11.2 Gold NPs

11.2.1 Different Shapes and Optical Properties

11.2.2 Conjugated (Covalent and Noncovalent)

11.2.3 Polymer/Polyelectrolyte Coating

11.2.4 Lipids

11.2.5 Composite

11.3 Magnetic NPs

11.3.1 Synthesis

11.3.2 Stabilization/Protection of Magnetic NPs

11.3.3 Hybrid Magnetic Nanosystem for Delivery

11.4 Metal Oxide NPs

11.4.1 Silica/Silicon

11.4.2 Calcium Phosphate, Hydroxyapatite

11.4.3 Others: Titanium Oxide and Aluminum Oxide

11.5 Others (Silver, Quantum Dots, and Lanthanides)

11.6 Conclusion and Perspective

Acknowledgment

References.

12: Scale-Up and cGMP Manufacturing of Nanodrug Delivery Systems for Clinical Investigations.

Notes:

Includes bibliographical references at the end of each chapters and index.

Description based on online resource; title from PDF title page (ebrary, viewed December 16, 2016).

ISBN:

9783527800698

3527800697

9783527800681

3527800689

OCLC:

965492723